Drug Profile
RS 89497
Latest Information Update: 17 Nov 2006
Price :
$50
*
At a glance
- Originator Roche Palo Alto LLC
- Class Antiarrhythmics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Arrhythmias
Most Recent Events
- 02 Apr 1997 No-Development-Reported for Arrhythmias in USA (Unknown route)
- 24 Oct 1994 Preclinical development for Arrhythmias in USA (Unknown route)